Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily

NCT00311402 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00311402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00311402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2006
Completion date
Not reported
Enrollment
1,295 (actual)
Sites
151

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrovascular accident